These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Palumbo A; Attal M; Roussel M Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441 [TBL] [Abstract][Full Text] [Related]
7. Treatment of newly diagnosed myeloma in patients not eligible for transplantation. Mateos MV; San-Miguel J Curr Hematol Malig Rep; 2011 Jun; 6(2):113-9. PubMed ID: 21347656 [TBL] [Abstract][Full Text] [Related]
8. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218 [TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment. Garrison LP; Wang ST; Huang H; Ba-Mancini A; Shi H; Chen K; Korves C; Dhawan R; Cakana A; van de Velde H; Corzo D; Duh MS Oncologist; 2013; 18(1):27-36. PubMed ID: 23299777 [TBL] [Abstract][Full Text] [Related]
10. Advances in therapy of multiple myeloma. Bladé J; Rosiñol L Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053 [TBL] [Abstract][Full Text] [Related]
14. Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Huang SY; Lin CW; Lin HH; Yao M; Tang JL; Wu SJ; Chen YC; Lu HY; Hou HA; Chen CY; Chou WC; Tsay W; Chou SJ; Tien HF Ann Hematol; 2014 Aug; 93(8):1371-80. PubMed ID: 24687382 [TBL] [Abstract][Full Text] [Related]
15. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187 [TBL] [Abstract][Full Text] [Related]
16. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Dimopoulos MA; Roussou M; Gkotzamanidou M; Nikitas N; Psimenou E; Mparmparoussi D; Matsouka C; Spyropoulou-Vlachou M; Terpos E; Kastritis E Leukemia; 2013 Feb; 27(2):423-9. PubMed ID: 22763386 [TBL] [Abstract][Full Text] [Related]